JP2018500014A5 - - Google Patents

Info

Publication number

JP2018500014A5

JP2018500014A5 JP2017529747A JP2017529747A JP2018500014A5 JP 2018500014 A5 JP2018500014 A5 JP 2018500014A5 JP 2017529747 A JP2017529747 A JP 2017529747A JP 2017529747 A JP2017529747 A JP 2017529747A JP 2018500014 A5 JP2018500014 A5 JP 2018500014A5

Authority

JP

Japan

Prior art keywords

variable region

chain variable

seq

sequence represented

amino acid

Prior art date

2015-12-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001413 amino acids Chemical class 0.000 claims description 462
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 224
• 239000000427 antigen Substances 0.000 claims description 104
• 102000036639 antigens Human genes 0.000 claims description 104
• 108091007433 antigens Proteins 0.000 claims description 104
• 239000012634 fragment Substances 0.000 claims description 63
• 206010028980 Neoplasm Diseases 0.000 claims description 27
• 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 18
• 102000046935 human TNFRSF17 Human genes 0.000 claims description 18
• 208000034578 Multiple myelomas Diseases 0.000 claims description 12
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
• 210000004027 cell Anatomy 0.000 claims description 12
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 6
• 229940127121 immunoconjugate Drugs 0.000 claims description 6
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 5
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
• 208000017604 Hodgkin disease Diseases 0.000 claims description 5
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 5
• 208000005017 glioblastoma Diseases 0.000 claims description 5
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 4
• 239000013604 expression vector Substances 0.000 claims description 4
• 150000007523 nucleic acids Chemical class 0.000 claims description 4
• 102000039446 nucleic acids Human genes 0.000 claims description 4
• 108020004707 nucleic acids Proteins 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 210000004881 tumor cell Anatomy 0.000 claims description 4
• 101710112752 Cytotoxin Proteins 0.000 claims description 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
• 239000002619 cytotoxin Substances 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 210000002865 immune cell Anatomy 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims 1
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 110
• 238000012986 modification Methods 0.000 description 106
• 230000004048 modification Effects 0.000 description 106
• 238000000034 method Methods 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 1